Charles River Laboratories International
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 2.9b | 3.5b | 4.0b | 4.1b | 4.0b | 4.2b | 4.5b |
% growth | 12 % | 21 % | 12 % | 4 % | (3 %) | 4 % | 8 % |
EBITDA | 768m | 820m | 986m | 1.0b | 997m | 1.1b | 1.2b |
% EBITDA margin | 26 % | 23 % | 25 % | 25 % | 25 % | 26 % | 26 % |
Profit | 364m | 391m | 486m | 475m | 322m | 432m | 533m |
% profit margin | 12 % | 11 % | 12 % | 11 % | 8 % | 10 % | 12 % |
EV / revenue | 4.8x | 6.0x | 3.4x | 3.5x | 3.1x | 2.8x | 2.5x |
EV / EBITDA | 18.4x | 26.1x | 13.8x | 14.1x | 12.3x | 11.1x | 9.7x |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | IPO | |
* | N/A | Post IPO Equity | |
$34.0m | Grant | ||
* | N/A | $500m | Post IPO Debt |
* | N/A | $1.0b | Post IPO Debt |
* | N/A | $1.3m | Grant |
Total Funding | $35.3m |
Recent News about Charles River Laboratories International
EditCharles River Laboratories, accessible via criver.com, is a pioneering company in the life sciences sector, dedicated to advancing the discovery, development, and safe manufacture of novel drugs and therapies. With a legacy of 70 years, Charles River has been at the forefront of innovation, particularly in the responsible advancement of alternative methods in animal research, focusing on replacement, reduction, and refinement.
The company operates in the biopharmaceutical market, serving a diverse clientele that includes pharmaceutical and biotechnology companies, government agencies, and academic institutions. Charles River offers a broad range of services, from basic research to comprehensive solutions for antibody discovery and cell therapy manufacturing. Their services are designed to accelerate the development of biopharmaceuticals from concept to cure, ensuring compliance with current Good Manufacturing Practices (CGMP).
Charles River's business model revolves around providing flexible and scalable testing platforms and manufacturing services. These platforms can be deployed at client facilities, satellite labs, or within Charles River's own extensive network of over 100 facilities in more than 20 countries. This flexibility allows clients to expedite their research and development processes efficiently.
Revenue generation for Charles River comes from offering specialized contract research and manufacturing services. These services include biologics contract manufacturing, antibody discovery, and cell therapy manufacturing, all tailored to meet the unique needs of their clients. Additionally, the company invests heavily in environmental, social, and governance (ESG) strategies, aiming to achieve 100% renewable electricity globally by 2030, which underscores their commitment to sustainability.
In summary, Charles River Laboratories is a key player in the life sciences industry, providing essential services that support the development of new drugs and therapies, with a strong emphasis on innovation, flexibility, and sustainability.
Keywords: biopharmaceuticals, antibody discovery, cell therapy, CGMP compliance, contract manufacturing, life sciences, drug development, ESG strategies, renewable electricity, supply chain integration.